AVTX
Avalo Therapeutics, Inc.NASDAQHealthcare$17.76+6.35%ClosedMarket Cap: $200.6M
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
2.63
P/S
3114.50
EV/EBITDA
-2.03
DCF Value
$0.99
FCF Yield
-28.0%
Div Yield
0.0%
Margins & Returns
Gross Margin
72.9%
Operating Margin
-123603.4%
Net Margin
-132642.4%
ROE
-77.9%
ROA
-67.2%
ROIC
-70.2%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $59.0K | 72.9% | $-19.7M | $-13.7M | $-0.74 | — |
| FY 2025 | $59.0K | -483.1% | $-72.9M | $-78.3M | $-5.84 | — |
| Q3 2025 | $0.00 | NaN% | $-19.2M | $-30.6M | $-2.19 | — |
| Q2 2025 | $0.00 | NaN% | $-19.3M | $-20.8M | $-1.92 | — |
| Q1 2025 | $0.00 | NaN% | $-14.7M | $-13.1M | $-1.25 | — |
| Q4 2024 | $192.0K | 54.7% | $-13.3M | $-35.3M | $10.47 | — |
| FY 2024 | $441.0K | 183.0% | $-68.5M | $-35.1M | $-3.26 | — |
| Q3 2024 | $249.0K | 386.7% | $-12.9M | $23.0M | $2.14 | — |
| Q2 2024 | $0.00 | -Infinity% | $-9.6M | $98.5M | $12.87 | — |
| Q1 2024 | $0.00 | Infinity% | $-32.8M | $-121.3M | $-141.14 | — |
| Q4 2023 | $571.0K | 138.7% | $-3.8M | $-8.2M | $-10.19 | — |
| FY 2023 | $1.9M | 33.3% | $-27.4M | $-31.5M | $-113.58 | — |